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Abstract
Background: The optimal vaccination strategy to mitigate the impact of influenza epidemics is unclear. In 2005, a
countywide school-based influenza vaccination campaign was launched in Knox County, Tennessee (population 385,899).
Approximately 41% and 48% of eligible county children aged 5–17 years were immunized with live attenuated influenza
vaccine before the 2005–2006 and 2006–2007 influenza seasons, respectively. We sought to determine the population
impact of this campaign.
Methods: Laboratory-confirmed influenza data defined influenza seasons. We calculated the incidence of medically
attended acute respiratory illness attributable to influenza in Knox and Knox-surrounding counties (concurrent controls)
during consecutive seasons (5 precampaign and 2 campaign seasons) using negative binomial regression and rate
difference methods. Age-stratified analyses compared the incidence of emergency department (ED) visits and
hospitalizations attributable to influenza.
Results: During precampaign seasons, estimated ED visit rates attributable to influenza were 12.39 (95% CI: 10.34–14.44) per
1000 Knox children aged 5–17 years and similar in Knox-surrounding counties. During the campaign seasons, annual Knox
influenza-associated ED visit rates declined relative to rates in Knox-surrounding counties: rate ratios 0.55 (95% CI: 0.27–
0.83) and 0.70 (95% CI: 0.56–0.84) for the first and second campaign seasons, respectively. Overall, there were about 35% or
4.86 per 1000 fewer influenza-associated ED visits among Knox County children aged 5–17 years attributable to the
campaign. No significant declines in Knox compared to surrounding counties were detected for influenza associated ED
visits in children aged ,5 years, all adults combined or selected adult age subgroups, although power for these analyses
was limited. Alternate rate-difference analyses yielded consistent results.
Conclusion: Vaccination of approximately 45% of Knox school-aged children with influenza vaccine was associated with a
35% annual reduction (4.86 per 1000) in ED visit rates attributable to influenza. Higher vaccination coverage and/or larger
studies would be needed to determine whether similar interventions have indirect benefits in other age groups.
Citation: Grijalva CG, Zhu Y, Simonsen L, Mitchel E, Griffin MR (2010) The Population Impact of a Large School-Based Influenza Vaccination Campaign. PLoS
ONE 5(11): e15097. doi:10.1371/journal.pone.0015097
Editor: Leo L. M. Poon, University of Hong Kong, Hong Kong
Received July 30, 2010; Accepted October 21, 2010; Published November 30, 2010
Copyright:  2010 Grijalva et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: CGG is supported by a Career Development Award (K01 IP000163) from the Centers for Disease Control and Prevention. This study was supported in
part by MedImmune LLC, the manufacturer of the live attenuated influenza vaccine. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: CGG and MRG received grant support from MedImmune and speaker honoraria and research support from Pfizer (for an unrelated study).
LS has received research support from Pfizer and consulting fees from SDI, a health data and analytics business. Other authors declared no competing interests.
The authors declare that these potential conflicts do not alter their adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: carlos.grijalva@vanderbilt.edu
Introduction
The optimal strategy to mitigate the population health impact of
influenza epidemics is unclear. Safe and effective vaccines are the
cornerstone for prevention of both seasonal and pandemic
influenza; however, coverage remains suboptimal in the US
despite long-standing recommendations for targeted vaccination of
high risk groups and seniors, and the recent expansion to universal
vaccination.[1,2,3,4]
Children are crucial transmitters of influenza virus within
communities.[5,6] School-aged children have high influenza
attack rates, are infected early in the course of epidemics, shed
viruses for longer periods than adults and have a higher intensity
of social contact than other age groups.[5,7,8,9] Therefore,
targeted vaccination of school-aged children, especially when
there is a good match between vaccine and circulating strains,
could reduce the impact of epidemics by preventing both influenza
disease in vaccinated children and also transmission of the virus to
other age groups.
Live attenuated influenza vaccines (LAIVs) are attractive for
school-based interventions because compared to inactivated
vaccines, they have higher efficacy in young children,[10,11,12]
result in reduced virus shedding among vaccinees after influenza
infection,[13] and their ‘‘needle-less’’ mode of administration has
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15097high acceptability.[11,14,15] School-based vaccination campaigns
with LAIV have been reported to reduce influenza illness among
vaccinees,[16,17,18] reduce influenza-like illnesses among their
close contacts, and modestly reduce school absenteeism.[16,17]
Although mathematical models and experimental evidence suggest
benefits of such targeted vaccination strategies among unvacci-
nated persons in selected populations (i.e. indirect or herd
protection), [9,19,20,21,22,23] consistent evidence of herd pro-
tection is limited.[14,16,24]
In 2005, Tennessee’s Knox County Health Department
launched a school-based influenza vaccination campaign with
the aim of immunizing public school children from kindergarten
through 12th grade. From October-December 2005, LAIV was
offered through weekday in-school and weekend clinics. Children
with signed parental consent forms and without known contrain-
dications to LAIV were vaccinated. MedImmune donated LAIV
and other campaign costs were assumed by the Knox County
Health Department.[18,25,26,27] Prior to the 2005–2006 influ-
enza season, 24,198 (45%) of 53,420 Knox public school students
were immunized with LAIV. Approximately 58% of 5,099
children aged 5–9 years received a second dose. In the following
2006–2007 campaign year, MedImmune donated LAIV and
additional resources to strengthen vaccination efforts and to
extend the campaign to private schools. Prior to the second (2006–
2007) season, 47% of 54,786 public school children and 61% of
5,998 private school children were immunized. Approximately
53% of children aged 5–9 years received a second dose. The
estimated overall coverage of eligible Knox school children aged
$5 years was 41% and 48% for the 2005–2006 and 2006–2007
influenza seasons, respectively.[18,25,26,27]
The second year of the Knox vaccination campaign (2006–
2007) was evaluated in two studies that compared influenza
activity in Knox with that of another urban Tennessee County.
These studies suggested that the campaign resulted in a reduction
in the proportion of influenza associated ED visits in school-aged
children and influenza hospitalizations in adults aged 50 to 64
years.[25,26] A third study reported that compared with children
from surrounding counties, Knox County children had a reduced
proportion of positive rapid influenza tests during the campaign
seasons (2005–2007).[18] Nevertheless, none of these studies could
quantify the campaign effects on actual ED and hospitalization
rates among school-aged children, and the effects on non-targeted
age groups remains unclear. In the present study we assessed the
population impact of the two-year countywide Knox influenza
vaccination campaign.
Methods
Ethics Statement
This study was approved by the Institutional Review Boards of
Vanderbilt University and the East Tennessee Children Hospital,
and by the State of Tennessee Department of Health. No informed
consent was needed for this retrospective study of information
already collected (See Healthcare encounters data section).
Overview
We performed a retrospective cohort study to estimate the
effectiveness of the Knox influenza vaccination campaign (2005–
2007) using data from seven consecutive influenza seasons (2000–
2001 through 2006–2007). Eight counties surrounding Knox
(Knox-surrounding counties), which had laboratory influenza
activity data and related healthcare utilization similar to Knox
during the five consecutive pre-campaign seasons, served as
concurrent controls.[28]
Laboratory-confirmed influenza infections and influenza
seasons
Results of rapid influenza tests from East Tennessee Children’s
Hospital, the regional hospital serving children from Knox and
Knox-surrounding counties, were used to define seven consecu-
tive influenza seasons, 2000–2001 through 2006–2007. Each
influenza season began the week when the cumulative proportion
of positive rapid influenza tests observed during that winter
(November through April) reached 2.5%, and ended the week the
cumulative proportion reached 97.5%. Thus, each season
contained at least 95% of all positive influenza tests from that
season.[18] Using the influenza seasonal information, we also
defined all non-influenza winter weeks as peri-Influenza sea-
son.[29]
Healthcare encounters data
We identified healthcare encounters using the electronic Tennes-
see Hospital Discharge Data System, which includes data on
hospitalizations and emergency department (ED) visits from all
Tennessee Department of Health-licensed hospitals. This informa-
tion is collected systematically for administrative purposes by
Tennessee Law mandate. Up to 9 diagnoses per record are coded
using International Classification of Diseases - Clinical Modification-
Ninth Revision (ICD9-CM) codes.
Study outcomes
We assessed the effects of the vaccination campaign on the excess
of medically attended acute respiratory illness (MAARI) observed
during influenza seasons, that is, the incidence of MAARI attri-
butable to influenza above seasonal baseline. MAARIs included
diagnoses (in any position) of otitis media, sinusitis, lower and upper
respiratory tract disease and fever (ICD9-CM: 381–383, 460–466,
480–487,490, 491, 493 and 7806).[14,30,31,32] All MAARI
hospitalizations and ED visits were mutually exclusive, and subjects
could contribute a maximum of one healthcare encounter per
setting per week, such that an ED visit and a hospitalization on the
same day qualified only as a hospitalization.
Statistical Analyses
Weekly MAARI rates were calculated using the weekly
number of MAARI, and population estimates obtained from
the US Census Bureau.[33] School-aged children (5–17 years old)
were the target population of the vaccination campaign and thus,
the primary population for this evaluation. Indirect (herd)
protection was assessed in other age groups: ,5, 18–49, 50–64
and 65 or more years. Furthermore, since vaccination uptake was
slightly higher among children attending kindergarten/elemen-
tary schools than among those attending middle/high school[18],
separate estimates were obtained for children aged 5–11 and 12–
17 years. We also obtained separate estimates for adults aged 18–
34 and 35–49 years old, as social contact patterns suggest that this
second group has higher intensity of contacts with school-aged
children [8].
To estimate weekly MAARI attributable to influenza (excess
MAARI) we first estimated the weekly rates that would be
expected in the absence of influenza. This baseline was calculated
using age-specific count-event models that included indicators for
calendar week, cyclical terms to account for seasonality and one
indicator for influenza activity (proportion of positive rapid
influenza tests)[34,35,36]. Since Poisson models showed data
overdispersion, we used more robust negative binomial models for
all estimations and allowed for non-linearity of the weekly time
term using restricted cubic splines. Using these models’ coeffi-
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estimated the predicted baseline weekly MAARI rates, that is, the
rates that would be expected in the absence of influenza
activity.[37,38] Excess MAARI was calculated as the difference
between observed MAARI weekly rates and the baseline predicted
rates during influenza seasons. Excess MAARI was set to 0 for
those weeks where predicted baseline exceeded the observed
incidence.[29,34,39]
In the secondary rate difference analysis,[29,34] age-specific
excess MAARI was estimated subtracting baseline estimates from
the observed values. We used MAARI rates during peri-influenza
seasons as the baseline over which we estimated the excess
MAARI.[34] Rate differences were set to 0 for those seasons
where the peri-Influenza season estimates exceeded the influenza
season estimates.[29,34,39]
Seasonal excess MAARI rates and 95% confidence intervals
were estimated separately for Knox and Knox-surrounding
counties, and compared using rate ratios.[18] Ninety-five percent
confidence intervals for these excess rate ratios were calculated
using the Delta method,[40] and negative estimates were
truncated at 0. Finally, the Knox campaign effectiveness was
estimated as (1-rate ratio) 6100% for each of the two campaign
seasons. All analyses were stratified by setting (ED visits and
hospitalizations). Statistical analyses were performed using SAS
9.1.3 and Stata 11.
Results
Study populations
The US Census Bureau estimated Knox County and Knox-
surrounding counties (eight counties) populations to number
385,899 and 422,064 people, respectively in 2000. Both populations
were predominantly white (88.7% vs. 96.1%), children aged 5–17
years accounted for 16.2% and 17% of the two populations, and
82.5% and 71.2% of those aged $25 years attained high school
graduation or higher education (Table 1).
MAARI ED visits and hospitalizations
During the seven consecutive winter seasons, there were 30630
MAARI ED visits and 1395 MAARI hospitalizations among Knox
children aged 5–17 years. In Knox-surrounding counties, the
numbers of ED visits and hospitalizations were 36670 and 1678,
respectively. The average number of weeks in each laboratory
defined-influenza season was 13 (range: 10–16 weeks).
Influenza activity
In both Knox and Knox-surrounding counties, MAARI ED
visit rates among children aged 5–17 years consistently peaked
during the influenza seasons (Figure 1).
For children aged 5–17 years, MAARI ED visit rates attributable
toinfluenza(excess MAARIEDvisits)inKnoxCounty rangedfrom
Table 1. Selected demographic characteristics of Knox and Knox-surrounding counties.
Knox County Knox-surrounding counties*
Total population (n) 385,899 422,064
Age groups (%)
,5 6.1 5.9
5t o1 7 16.2 17.0
18 to 49 49.5 44.3
50 to 64 15.6 18.4
65 or more 12.6 14.4
Gender (%)
Female 51.7 51.4
Race (%)
White 88.7 96.1
Black 8.7 2.2
Other 2.6 1.7
Enrolled in school (aged $3 years) (%)
Nursery school, preschool 6.1 5.1
Kindergarten 4.7 5.7
Elementary school (grades 1–8) 37.8 50.5
High school (grades 9–12) 18.3 23.5
College or graduate school 33.1 15.3
Educational attainment (aged $25 years) (%)
High school graduate or higher 82.5 71.2
Bachelor’s degree or higher 29 13.8
Income
Median household income (US$) 37,454 33,731
Families below poverty level (%) 8.4 10.6
*Data are from the US Census Bureau for year 2000.
doi:10.1371/journal.pone.0015097.t001
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1000 in Knox surrounding counties. MAARI hospitalization rates
attributable to influenzain Knox County rangedfrom 0.2to 0.5per
1000, and from 0.3 to 0.6 per 1000 in Knox-surrounding counties.
MAARI ED visits and hospitalization rates attributable to
influenza were similar in Knox and Knox-surrounding counties
during the pre-campaign seasons (Tables 2 and 3).[28]
Effectiveness of the Knox Vaccination campaign
During the campaign years, the ratio of ED visit rates
attributable to influenza among children aged 5–17 years (target
population) declined significantly, indicating that ED rates
attributable to influenza in Knox decreased compared with the
rates in Knox-surrounding counties. The ratio of rates in Knox
and Knox-surrounding counties was 0.55 (95% CI: 0.27–0.83) and
0.70 (95% CI: 0.56–0.84) during the first and second year of the
vaccination campaign, respectively (Figure 2).
Overall, the ratio of average ED visit rates during the pre-
campaign seasons (2000–2005) and during the campaign seasons
(2005–2007) was 0.95 (0.74, 1.16) and 0.65 (0.46, 0.84),
respectively (Table 2). During the campaign, the average influenza
associated ED rates in Knox were 9.11 (95% CI: 6.94, 11.28)
compared to 13.97 (95% CI: 11.79, 16.15) per 1000 in Knox-
surrounding counties. Similar results were observed among
children aged 5–11 and 12–17 years old (Table 2). Hence, the
estimated overall effectiveness of the vaccination campaign in
Figure 1. Influenza activity among school-aged children, Emergency Department (ED) visits, 2000–2007. Footnote: The green line
represents the model predicted baseline rates. That is, the rates that would be expected in the absence of influenza activity.
doi:10.1371/journal.pone.0015097.g001
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17 years was estimated to be 35% (95% CI: 16–54), translating to
4.86 fewer ED visits per 1000 Knox County children annually.
MAARI hospitalization rates attributable to influenza among
children aged 5–17 years from Knox and Knox-surrounding
counties were similar during the pre-campaign and campaign
seasons. The rate ratios remained relatively stable and were not
different from 1 throughout the study period. The ratios of
average hospitalization rates during the pre-campaign and
campaign seasons were not significantly different from 1. Similar
results were observed among children aged 5–11 and 12–17 years
old (Table 3).
MAARI incidence attributable to influenza among other age
groups not targeted by the Knox campaign (children aged ,5
years, all adults combined and selected adult age subgroups)
remained similar throughout the study years in both Knox and in
Knox-surrounding counties. In these groups, rate ratios of ED visit
rates and hospitalizations attributable to influenza for Knox and
Knox-surrounding counties were not different from 1 (Tables 2
and 3).
Results from the rate difference analysis were consistent with the
primary analysis, indicating that rates of ED visits attributable to
influenza in the target population (children aged 5–17 years) were
0 and 6.1 per 1000 (rate ratio could not be computed) during the
first campaign season for Knox and Knox-surrounding counties,
respectively. During the second campaign season rates were 14.8
and 20.7 per 1000 (rate ratio 0.71, 95% CI: 0.58–0.84). Results for
non-targeted age groups were, in general, similar to those from the
primary analyses (See Supporting Information Tables S1 and S2).
Discussion
Our findings indicate that the large Knox school-based
influenza vaccination campaign was associated with a significant
reduction in morbidity attributable to influenza. These declines
coincided temporally with the vaccination campaign and were
observed exclusively in the 5–17 year old target population of the
campaign, with consistent results observed in secondary analyses.
Nevertheless, our study had limited power to detect significant
declines among non-targeted age groups, and none were detected.
Table 2. Ratios of excess MAARI rates of ED visits attributable to influenza (Knox/Knox-surrounding counties).
Pre-Campaign seasons Campaign seasons
Age group
Knox
rate/1000
Knox-surrounding
rate/1000
Excess Rate ratio
(95% CI)
Knox
rate/1000
Knox-surrounding
rate/1000
Excess Rate ratio
(95% CI)
,5 years 38.73 40.18 0.96 (0.73, 1.19) 30.18 33.72 0.90 (0.60, 1.20)
5 to 17 years 12.39 13.02 0.95 (0.74, 1.16) 9.11 13.97 0.65 (0.46, 0.84)*
5 to 11 years 14.78 14.87 0.99 (0.71, 1.27) 11.71 17.50 0.67 (0.44, 0.90)*
12 to 17 years 9.97 11.16 0.89 (0.59, 1.19) 6.72 10.12 0.66 (0.34, 0.98)*
18 to 49 years 4.44 5.22 0.85 (0.63, 1.07) 2.95 3.52 0.84 (0.48, 1.20)
18 to 34 years 5.55 7.33 0.76 (0.53, 0.99)* 3.64 4.69 0.78 (0.38, 1.18)
35 to 49 years 3.32 3.48 0.95 (0.51, 1.39) 2.48 2.61 0.95 (0.31, 1.59)
50 to 64 years 2.92 3.07 0.95 (0.46, 1.44) 2.35 2.04 1.15 (0.23, 2.07)
65 or more years 3.38 3.46 0.98 (0.49, 1.47) 2.42 2.44 0.99 (0.21, 1.77)
18 or more years 3.90 4.31 0.90 (0.71, 1.09) 2.66 2.83 0.94 (0.61, 1.27)
Footnote: *Indicate significant change. Excess rate ratio 95% confidence intervals (CI) did not include 1.
doi:10.1371/journal.pone.0015097.t002
Table 3. Ratios of excess MAARI rates of hospitalization attributable to influenza (Knox/Knox-surrounding counties).
Pre-Campaign seasons Campaign seasons
Age group
Knox
rate/1000
Knox-surrounding
rate/1000
Excess Rate ratio
(95% CI)
Knox
rate/1000
Knox-surrounding
rate/1000
Excess Rate ratio
(95% CI)
,5 years 3.15 3.98 0.79 (0.12, 1.46) 2.17 2.58 0.84 (0, 1.94)
5 to 17 years 0.37 0.45 0.82 (0, 1.98) 0.41 0.44 0.93 (0, 2.38)
5 to 11 years 0.45 0.57 0.79 (0, 2.13) 0.47 0.56 0.84 (0, 2.31)
12 to 17 years 0.44 0.43 1.02 (0, 2.69) 0.53 0.57 0.93 (0, 2.56)
18 to 49 years 0.39 0.49 0.80 (0, 1.63) 0.27 0.49 0.55 (0, 1.46)
18 to 34 years 0.46 0.41 1.12 (0, 2.53) 0.43 0.54 0.8 (0, 1.91)
35 to 49 years 0.39 0.68 0.57 (0, 1.43) 0.30 0.58 0.52 (0, 1.76)
50 to 64 years 1.3 1.75 0.74 (0.04, 1.44) 1.14 1.38 0.83 (0, 1.96)
65 or more years 3.75 4.49 0.84 (0.33, 1.35) 2.95 3.32 0.89 (0.05, 1.73)
18 or more years 1.02 1.49 0.68 (0.34, 1.02) 0.63 1.13 0.56 (0.06, 1.06)
doi:10.1371/journal.pone.0015097.t003
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declined in the target population, indicating a direct protection of
the vaccination campaign. No significant effects were observed on
MAARI hospitalizations but these events were rare, and despite
the large sample size of our study, we could not rule out sizable
campaign effects on this outcome. Based on the analyses of data
from pre-campaign years for the target population, we previously
estimated that our study would be powered to detect a 20%
decline in ED visits rates, but a much larger 91% decline in
hospitalization rates.[28]
Although previous studies suggested that indirect protection of
unvaccinated groups against influenza-like-illness and reductions
in absenteeism could be achieved through vaccination of school-
aged children,[14,15,16,17,41,42] we were unable to show sig-
nificant disease reductions among age groups that were not
directly targeted during the Knox vaccination campaign. It is
possible that the influenza vaccination coverage among school
children (approximately 45%) was not high enough to achieve
significant protective levels in other groups. A previous study
reported significant indirect protection against MAARI among
adults aged $35 years with even lower vaccination coverage of
children aged 1.5 through 18 years (e.g. approximately 25%, 35%
and 50% coverage during three consecutive influenza sea-
sons).[14] However, in that study significant protection was not
demonstrated among children or younger adults who were
vaccinated.[14] It is important to note that most contemporary
school or community-based influenza studies have achieved
vaccination coverage of 50% or lower.[14,15,16] The feasibility
of achieving higher vaccination coverage through promotion or
education campaigns deserves further scrutiny.
Another factor limiting the ability of this study to demonstrate
indirect effects could be vaccination coverage among non-targeted
age groups. Prior studies showed parent/self-reported vaccination
rates in Knox County residents of 36% for children aged ,5y e a r s
and 70% for adults aged 50 years or older.[25,26] Detecting indirect
protection in populations where influenza vaccination is now
universally recommended will be challenging, and limited to
reductions in the residual disease burden in those populations. A
recent article assessed the effect of school-based influenza vaccina-
tion on healthcare encounters in the Province of Ontario, Canada
Figure 2. Estimated rates and rate ratio of Emergency Department (ED) visits and hospitalization rates attributable to influenza
among school-aged children from Knox and Knox-surrounding counties.
doi:10.1371/journal.pone.0015097.g002
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tion program since year 2000. Within this context, Kwong et al[43]
compared the incidence of influenza associated healthcare encoun-
ters between public health units (PHUs) that had school-based
influenza vaccination available in at least 50% of elementary and
secondary schools, with PHUswithout such availability. Vaccination
coverage in children in secondary schools was 39% in PHUs with
and 30% in those without vaccination programs available. There
was a modest reduction in the frequency of physician office visits for
influenza-associated pneumonia and influenza in children attending
secondary schools in PHUs with vaccination programs compared to
those without such programs (estimated vaccine effectiveness: 19%),
but no significant reductions in emergency department visits or
hospitalizations among school aged-children. There were no
significant differences in visits for the more common influenza-
associated acute respiratory illnesses in the targeted age group; and,
similar to our study, no benefits were detected in other non-targeted
groups.[43]
A recent cluster randomized clinical trial demonstrated that
vaccination of 83% of children aged 3–15 years in Hutterite
colonies significantly reduced the incidence of influenza illness in
both immunized children and their unvaccinated close contacts.
Although the study also reported non-significant declines in
physician visits for respiratory diseases and influenza like-illnesses
in colonies randomized to influenza vaccines, the trial was not
adequately powered to assess these outcomes.[20] The very high
vaccine coverage achieved, the particular demographics and low
background vaccination coverage in the study communities likely
contributed to the observed indirect protection. Additional studies
in populations with low background vaccination rates may help
quantify the minimum vaccination coverage required to attain
measureable indirect benefits.[24]
The identification of a proper comparison population had
implications for our assessment of effectiveness. Previous studies
have demonstrated substantial differences in the seasonal incidence
of influenza-related healthcare encounters between different
communities.[44] Our assessment of the campaign effectiveness
used Knox-surrounding counties as comparison because in spite of
minordemographicdifferencesbetweenstudypopulations(Table1),
the incidence of healthcare utilization attributable to influenza was
similar in five consecutive pre-campaign influenza seasons.[28]
The two different analytical approaches used to estimate MAARI
attributable to influenza found similar estimates.[34] Our analyses
suggest that the overall effectiveness of the Knox campaign in
preventing ED visits among children aged 5–17 years was 35%
(95% CI: 16–54). This estimate encompassed both direct and
indirectprotectioninthis age group,[43]and suggeststhattheKnox
vaccination campaign prevented approximately 300 influenza ED
visits in this target population during each influenza season. Using
the estimated effectiveness, we also calculated crude estimates of
vaccine efficacy for Knox children aged 5–17 years. Taking into
account that ,45% of all Knox school-aged children were
immunized, the observed excess rate ratio of 0.65 and assuming
that influenza rates were the same for unvaccinated children from
Knox and Knox-surrounding counties, the estimated vaccine
efficacy provided by LAIV against ED visits would be 77.8%
(RR: 0.65=[12(0.45*Vaccine Efficacy)]/1). These estimates as-
sumed no vaccination of school-aged children in Knox-surrounding
counties; accounting for influenza vaccination in control commu-
nities would increase the vaccine efficacy estimates.
We used all data available for ED visits and hospitalizations for
the study populations. This information was systematically
collected for administrative purposes and thus, unlikely to be
affected by recall issues. Study data included all hospital-based
care without regard to payment sources and thus it was virtually
free of selection issues. Moreover, the use of laboratory-confirmed
influenza information to define influenza seasons reduced
misclassification of periods with influenza activity.
Despite those strengths, the interpretation of our findings
requires the consideration of several caveats. First, our data lacked
virological confirmation for all observed MAARIs and potential
misclassification of MAARI attributable to influenza cannot be
ruled out. Nevertheless, our estimates were restricted to labora-
tory-confirmed influenza seasons and we consider that any
residual misclassification would be similar in the two study
populations. Second, despite its large sample size, our study did
not detect significant changes in the non-targeted adult population
combined, and had limited power to identify significant effects of
the intervention on ED visits for adult age subgroups. Moreover,
the limited number of hospitalizations observed reduced our
ability to detect true effects on this outcome. Third, information on
other potential causes of MAARI during winter months (e.g.
respiratory syncytial virus [RSV]) was not specifically accounted
for in our analyses. However, previously studies suggest that
estimates including or excluding RSV data did not significantly
affect influenza estimates.[29,36,45] Also, RSV activity would be
of greater concern in younger age groups than among children
aged 5-17 years. Nevertheless, lack of adjustment for RSV illness
may have limited our ability to detect indirect protection in
children aged ,5 years. Finally, we did not measure influenza
vaccination coverage in other age groups. High vaccination rates
in seniors and other age groups may have made it difficult to
demonstrate indirect effects in these groups.
In conclusion, our findings indicate that a large school-based
influenza vaccination campaign with LAIV that attained 45%
vaccination coverage, significantly reduced ED visit rates attrib-
utable to influenza among Knox County children aged 5–17 years,
the main target of the campaign. During campaign years there
were approximately 5 fewer influenza-associated ED visits per
1000 Knox children aged 5–17 years annually. Higher vaccination
coverage and/or larger studies will be needed to determine the
effect of similar interventions in other age groups.
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